<DOC>
	<DOCNO>NCT00926016</DOCNO>
	<brief_summary>The purpose study determine rosiglitazone , medicine use treat diabetes , improve response anti-viral treatment .</brief_summary>
	<brief_title>Pioglitazone Viral Kinetics , Cytokines Innate Immunity Insulin Resistant CHC GT 1 Subjects</brief_title>
	<detailed_description>The aim study determine insulin sensitize thiazolidinedione ( TZD ) improve ( 1 ) baseline viremia , ( 2 ) enhance viral kinetics , ( 3 ) improve cytokine profile ( 4 ) regulate innate cellular immunity ( presumably adaptive immunity regulate well ) measure bioactivity collect biomarkers .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>HCVAb HCVRNA PCR Positive least six month ( rule acute seroconversion ) Serum positive HCVRNA PCR assay Must insulin resistance , define QUICKI score &lt; 0.35 . QUICKI Liver biopsy consistent CHC within 24 month prior enrollment Compensated liver disease follow minimum hematological , biochemical , serologic criterion Screening Visit ( WNL = within normal limit ) : Hemoglobin value &gt; 12 gm/dL female &gt; 13 gm/dL male . WBC &gt; 3,000/ mm3 Neutrophil count &gt; 1,500/mm3 Platelets &gt; 65,000/ mm3 Direct bilirubin , within 20 % ULN Indirect bilirubin , within normal limit ( WNL ) Albumin &gt; 3gm/dL Serum creatinine &lt; 20 % ULN TSH WNL Alpha fetoprotein value &lt; 100 ng/mL Prior interferon base therapy Use insulin Fasting glucose level &gt; 200 mg/dl Women pregnant breastfeed No thiazolidinedione liver biopsy and/or entire study ( Hepatitis C nongenotype 1 Suspected hypersensitivity pioglitazone Any cause liver disease chronic hepatitis C , insulin resistance , NAFLD , include limited : Hemochromatosis Alpha1 antitrypsin deficiency Coinfection HBV Wilson 's disease Autoimmune hepatitis Significant alcohol use Drugrelated liver disease Any condition would prevent subject liver biopsy . Hemoglobinopathies could potentially compromise patient safety Evidence advance liver disease history presence ascites , bleed varix , spontaneous encephalopathy . Participants organ transplant cornea hair transplant . Any known preexisting medical condition could interfere subject 's participation completion protocol : Preexisting psychiatric condition , especially severe depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt exclude Substance abuse , alcohol , IV drug inhale drug Alcohol consumption strongly discourage Seizure disorder control medication Significant cardiovascular dysfunction within past 12 month Chronic pulmonary disease document pulmonary hypertension Immunologically mediate disease [ e.g. , inflammatory bowel disease ( Crohn 's disease , ulcerative colitis ) ] , rheumatoid arthritis , idiopathic thrombocytopenia purpura , systemic lupus erythematosis , autoimmune hemolytic anemia , scleroderma , severe psoriasis , clinical cryoglobulinemia vasculitis Any medical condition requiring , likely require , chronic systemic administration steroid course study Evidence active suspect cancer history malignancy risk reoccurrence â‰¥ 20 % within two year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>